Abstract: A method of identifying alleles of polymorphic sites in a plurality of nucleic acid samples including the steps of determining a source tag sharing number “d” for each of the alleles; performing a first reaction in a plurality of pools of the alleles to be identified to produce reaction products including a source tag identifying said each pool; pooling the pools to provide pooled pools; for each of the alleles to be identified, performing a second reaction using said reaction products to produce allele-specific second reaction products comprising a marker tag and a derived source tag; identifying said allele-specific second reaction products to identify the alleles. If “d” is equal to or larger than a maximum pool size, the first reaction may not be performed. Alleles may be binned together. A microparticle comprising one or more capture probes each comprising an oligonucleotide complementary to a subsequence of a target polynucleotide.

Abstract: A biomolecule analysis kit includes a reaction container configured to perform an enzymatic reaction, the reaction container including a base portion which has a container-shaped portion and a low-adsorption structural portion which is provided on at least the inner surface of the container-shaped portion, the low-adsorption structural portion having an adsorption rate lower than the base portion at which at least one of a sample which becomes a target of analysis in the enzymatic reaction and a reagent for the enzymatic reaction is adsorbed thereonto, wherein a signal resulting from the enzymatic reaction is configured to be detected when the enzymatic reaction is performed in the reaction container.

Abstract: Disclosed are systems and methods for resequencing using color calls. A DNA sample is encoded and sequenced according to a multi-base code producing a string of read color calls for a fragment of the sample. A reference sequence is obtained. The string of read color calls is mapped to the reference sequence. A base sequence is extracted from the reference sequence. The base sequence is encoded as a string of reference color codes according to the multi-base code. The string of read color calls is aligned with the string of reference color codes and mismatches in the alignment are detected. One or more mismatches of the string of read color calls are annotated as inconsistent. The one or more inconsistent mismatches of the string of read color calls are corrected. The string of corrected read color calls is decoded to bases producing a read sequence.

Abstract: Methods, system, and kits are provided for sample identification, and, more specifically, for designing, and/or making, and/or using sample discriminating codes or barcodes for identifying sample nucleic acids or other biomolecules or polymers. For example, a plurality of flowspace codewords may be generated, the codewords comprising a string of characters. A location for at least one padding character within the flowspace codewords may be determined. The padding character may be inserted into the flowspace codewords at the determined location. After the inserting, a plurality of the flowspace codewords may be selected based on satisfying a predetermined minimum distance criteria, wherein the selected codewords correspond to valid base space sequences according to a predetermined flow order. And the barcode sequences corresponding to the selected codewords may be manufactured.

Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract: A precise measurement of the immunological receptor diversity present in a sample is obtained by sequence analysis. Samples of interest are generally complex, comprising more than 102, 103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012 or more different sequences for a receptor of interest. Immunological receptors of interest include immunoglobulins, T cell antigen receptors, and major histocompatibility receptors. The specific composition of immunological receptor sequence variations in the sample can be recorded and output. The composition is useful for predictive, diagnostic and therapeutic methods relating to the immune capabilities and history of an individual. Such predictions and diagnoses are used to guide clinical decisions.

Abstract: The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.

Abstract: The invention provides a collection of gene expression signatures that is linked to longevity. Also provided herein are assays, methods, and systems for identifying a treatment that can modulate lifespan or determining an effect of a treatment on a health profile of a subject by using the collection of gene expression signatures described herein.

Abstract: The present invention provides nucleic acid markers for rapid diagnosis of KD and a kit for detection of the nucleic acid markers. The nucleic acid markers are 4 miRNAs, and the kit comprises primers for quantitative detection of the 4 miRNAs by fluorescent quantitative PCR. The diagnosis of KD can be performed only by quantificationally detecting the contents of the 4 miRNAs in serum exosomes and then analyzing the Ct values of the 4 miRNAs. The present invention possesses the advantages of easily-obtained sample, simple operation, high specificity, time saving, accurate and reliable detection result, etc., so children with KD can be timely and accurately diagnosed. Particularly, KD can be easily distinguished from common virus infection with similar symptoms only by one test. The present invention may play an important role in rapid diagnosis of KD of children and further provide a direction for developing rapid diagnostic kit of KD.

Abstract: The present disclosure generally pertains to a method for developing diagnostic tests that are based on the immune response and the resulting immune repertoire. The presently disclosed method increases the signal and reduces the background to allow the identification of shared CDR3s that can be used to produce a disease signature. The presently disclosed method may be used to develop a diagnostic test for different diseases including, but not limited to, cancer, autoimmune disease, inflammatory disease and infectious disease.

Abstract: A method for monitoring a treatment of a subject having a musculoskeletal disorder is provided. The method includes measuring a first expression level of at least two biomarkers at a treatment site prior to the treatment and measuring a second expression level of the at least two biomarkers at the treatment site after the treatment begins. The method further includes comparing the first expression level of the at least two biomarkers prior to the treatment to the second expression level of the at least two biomarkers post treatment and continuing the treatment, altering the treatment or stopping the treatment based on the comparison. A method of treating a musculoskeletal disorder in a subject is also provided. The method includes removing a aggrecan-hyaluronan matrix from a treatment site in the subject.

Abstract: Disclosed herein are weight analysis methods and assays, which objectively identify biological strengths and weaknesses in a patient's genetic coding that affect their weight. The generated results can be utilized to develop a personalized weight and nutritional regimen to regulate weight and prevent, reduce and treat weight disorders and diseases. In some embodiments, a method of characterizing a subject's weight is provided which includes generating a personalized weight profile by determining a subject's genetic potential in at least one area of weight health by analyzing one or more weight health-associated single nucleotide polymorphisms (SNPs) or other genetic markers associated with the particular area of weight health being assessed in a sample obtained from the subject.

Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.

Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.

Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.

Abstract: A method for quantifying the expression level of human WT1 mRNA conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation. The method is for quantifying the expression level of human WT1 mRNA by one-step RT-PCR and comprises simultaneously subjecting the human WT1 mRNA and a housekeeping gene (mRNA) to reverse transcription and extension reactions carried out sequentially in the same vessel.

Abstract: The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.

Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

Abstract: Described herein are methods and assays for determining the presence or absence of certain markers useful in informing treatment of one or more subjects with one or more activin inhibitors. In certain aspects the one or more subjects can have cancer. In certain aspects the markers can include INHBA and ACVR2B. In certain aspects one or more subjects can be treated with an activin inhibitor.

Abstract: Gene signatures that are predictive of the sensitivity of a cancer or tumor to an MDM2i or an antagonist of the MDM2-p53 interaction. Differentially expressed genes in the provided gene signatures serve as biomarkers assessing the sensitivity of cancer and tumor samples to treatment or therapy with an MDM2i. Also provided are methods of determining MDM2i sensitivity of different cancer and tumor types and subtypes, based on the expression of genes in the MDM2i sensitive gene signatures, and treating individuals with an MDM2i if their cancers are determined to be MDM2i-sensitive. TP53 gene and p53 protein status can be determined for the samples undergoing analysis for MDM2i sensitivity. Methods, platforms, kits, reagents, and compositions of the invention provide advantageous approaches and tools for personalized or individualized treatments of cancer patients whose cancers exhibit sensitivity to MDM2 inhibitors.

Abstract: Disclosed is a gene expression panel that can be used to predict prostate cancer (PCa) progression. Some embodiments provide methods for predicting clinical recurrence of PCa. Some embodiments provide a method for predicting progression of prostate cancer in an individual, the method comprising: (a) receiving expression levels of a collection of signature genes from a biological sample taken from said individual, wherein said collection of signature genes comprises at least two genes selected from the group consisting of: NKX2-1, UPK1A, ADRA2C, ABCC11, MMP11, CPVL, ZYG11A, CLEC4F, OAS2, PGC, UPK3B, PCBP3, ABLIM1, EDARADD, GPR81, MYBPC1, F10, KCNA3, GLDC, KCNQ2, RAPGEF1, TUBB2B, MB, DUOXA1, C2orf43, DUOX1, PCA3 and NPR3; (b) applying the expression levels to a predictive model relating expression levels of said collection of signature genes with prostate cancer progression; and (c) evaluating an output of said predictive model to predict progression of prostate cancer in said individual.

Abstract: There is provided herein, systems, devices and methods for determining a risk of recurrence of cancer following a cancer therapy of a patient by determining genomic instability of a tumour. There is further provided systems, devices and methods for categorizing a patient into a prognostic cancer sub-group by using copy number alterations.

Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize NY-BR-1 are disclosed. Chimeric antigen receptors (CARs), anti-NY-BR-1 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Abstract: The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.

Abstract: Analyzing peripheral blood RNA populations presents an effective, accurate, minimally invasive method of determining a patient's cancer status. Using circulating free RNA of the genes disclosed herein, systems and methods are disclosed which can accurately identify cancer signatures in the patient blood samples.

Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.

Abstract: [PROBLEM TO BE SOLVED] An object of the present invention is to provide a novel tumor marker and use thereof. In more detail, the present invention provides a novel tumor marker, a method for measuring said tumor marker and a measurement kit, a method for detecting cancer using the same, a kit for detecting cancer, a method for screening a preventive and/or therapeutic agent for cancer, as well as a medicament such as cancer vaccine. [SOLUTION] According to the present invention, a method for measuring an alternative splicing variant of OATP1B3 mRNA in a sample to be examined is provided. Said measurement method comprises measuring mRNA comprising a nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing table in a sample to be examined isolated from living organism with differentiation from a mRNA comprising a nucleotide sequence represented by SEQ ID NO: 2. Said measurement method is useful for detecting cancer or screening a preventive and/or therapeutic agent.

Abstract: Differentially expressed miRNA or small mRNA in the culture media of embryos were found to correlate to and affect embryo developmental fate. Accordingly the present invention provides a method for selecting a bovine embryo for implantation into a female bovine animal for further development based on the levels of specific miRNA or small mRNA. Also provided are methods of improving bovine embryo development fate by reducing in the culture medium the level of selected miRNAs.

Abstract: A protein reporter system comprising at least one reporter including a response element responsive to the binding of a transcription factor, a secreted enzyme backbone and a recognition region for specific binding of an antibody. Multiplexed assays for binding, assaying and quantifying the activity of transcription factors are also described, in which the assays use protein reporters in sets, libraries or other groupings, as necessary to achieve desired quantification.

Abstract: A process for the removal of contaminants from a liquor, including two or more of carbonatation, phosphatation and sulphitation of the liquor to form a precipitate having at least some of the contaminants from the liquor, and separating the precipitate from the liquor. The processes may be included in sugar refining or water decontamination processes.

Abstract: The inventions relate to the field of metallurgy, and specifically to a method for producing steel and to a design for an electric arc furnace for implementing same. The method involves loading a charge into a workspace of a furnace, said charge consisting of scrap metal and of agglomerated oxy-carbon materials, inputting electric energy, fuel, a carburizer, a flux and gaseous oxygen, heating and melting the charge using electric arcs with the decarburization of a metal bath, and releasing metal and slag from the furnace. Prior to melting, a portion of the oxy-carbon materials is loaded, simultaneously with a first portion of metal charge, into the central zone of the furnace, and the remaining oxy-carbon materials are introduced into the melted charge during the melting process at a specific loading speed of 0.5-10 kg/min per 1 megavolt-ampere of power of the transformer of the electric arc furnace, and the size of the pieces of oxy-carbon materials is selected to be between 5 and 80 millimeters.

Abstract: The present disclosures and inventions relate to a method for producing Si-killed steel comprising: a) supplying Al-killed steel ladle furnace slag; and b) adding the Al-killed steel ladle furnace slag to a Si-killed steel process to thereby produce Si-killed steel.

Abstract: The present invention provides a case hardening steel which satisfies the following expression (1) representing a relationship between a maximum deformation resistance ?MAX (MPa) and a DI value, the maximum deformation resistance ?MAX (MPa) being obtained when a test piece which has a size of ?15×22.5 mm and is cut out from a material after spheroidizing, is subjected to compressive deformation by cold forging at a compression ratio of 70% in a state that an end surface thereof is restrained, and the DI value being obtained from a Jominy quenching test: ?MAX<12.8×DI+745 . . . Expression (1). Additionally, the present invention obtains a carburized part by subjecting the case hardening steel to carburizing and quenching.

Abstract: A delivery device that is usable in a laser peening operation emits a columnar flow of a fluid that contains therein a beam of electromagnetic energy. The beam is retained within the interior of the flow of fluid since the total internal reflectivity of the flow is sufficient to do so. The flow of fluid that serves as a conduit for the beam also itself impinges on a workpiece and thus contains and washes away the plasma that forms from a laser peening operation, and this resists the plasma from reaching and possibly damaging the delivery device. The carrying of the beam in the columnar flow of fluid avoids the need to maintain a fixed distance between the delivery device and the workpiece, which simplifies the movement by a robotic manipulator of the delivery device along a non-planar surface of a workpiece during a laser peening operation.

Abstract: A formed material can include a composition having a non-recrystallized portion and a recrystallized layer of the composition having predetermined depth, the recrystallized layer forming at least part of a surface of the composition that overlays the non-recrystallized portion. A method of forming a material having an at least partially recrystallized layer can include forming a composition into a predetermined shape having a surface, wherein the forming leaves the surface of the composition in a non-recrystallized state. The method can also include determining a desired depth of at least a portion of a recrystallized layer at the surface and recrystallizing at least a portion of the surface of the composition to form the recrystallized layer to the desired depth.

Abstract: A magnetic domain refining treatment is performed by dividing a surface of a steel sheet into a plurality of regions in a widthwise direction, disposing a laser irradiation apparatus or an electron beam irradiation apparatus in each of the regions, and forming beam-irradiated regions through beam irradiation, wherein beams are irradiated so that a nature of a juncture between beam-irradiated regions satisfies 0???0.3×a and ?1.2×a+0.02×w?0.5×??6.5????0.13×a?200×(1/w)+5.4 when TD spacing ? at the juncture between the beam-irradiated regions is ?3 to 0 mm, whereby a grain oriented electrical steel sheet having an excellent iron loss property is produced in a good productivity.

Abstract: Provided is a multilayer cutting blade (1) including a core (2) that has a cutting wire (3), two side flanks (5), and two intermediate connecting thicknesses (4), the side flanks (5) being made of a corrosion-resistant tough metal alloy, each intermediate connecting thickness (4) having a first face (8) for connecting to the core (2) and a second face (9) for connecting to one or the other of the side flanks (5), the first connecting face (8) and the second connecting face (9) being made of copper or a copper alloy. The core (2) is made of martensitic stainless steel, and the thickness of the core (2) is greater than or equal to one third of the thickness of the cutting blade (1), and preferably greater than or equal to half the thickness of the cutting blade (1).

Abstract: A bearing part according the present invention includes: C: 0.95% to 1.10%; Si: 0.10% to 0.70%; Mn: 0.20% to 1.20%; Cr: 0.90% to 1.60%; Al: 0.010% to 0.100%; N: 0.003% to 0.030%; P: 0.025% or less; S: 0.025% or less; O: 0.0010% or less; optionally one or more of the group consisting of Mo: 0.25% or less, B: 0.0050% or less, Cu: 1.0% or less, Ni: 3.0% or less, and Ca: 0.0015% or less; and a remainder including Fe and impurities; wherein a metallographic structure includes a retained austenite, a spherical cementite and a martensite; in which an amount of the retained austenite is 18% to 25%, by volume %; an average grain size of a prior-austenite is 6.0 ?m or less; an average grain size of the spherical cementite is 0.45 ?m or less; and a number density of the spherical cementite is 0.45×106 mm?2 or more in the metallographic structure.

Abstract: A bearing part according the present invention includes, as the chemical composition, by mass %, C: 0.95% to 1.10%, Si: 0.10% to 0.70%, Mn: 0.20% to 1.20%, Cr: 0.90% to 1.60%, Al: 0.010% to 0.100%, N: 0.003% to 0.030%, P: 0.025% or less, S: 0.025% or less, O: 0.0010% or less, and optionally Mo: 0.25% or less, B: 0.0050% or less, Cu: 1.0% or less, Ni: 3.0% or less, and Ca: 0.0015% or less, and a remainder including Fe and impurities; metallographic structure includes a retained austenite, a spherical cementite and a martensite; an amount of the retained austenite is 15% to 25%, by volume %; an average grain size of prior-austenite is 8.0 ?m or less; and a number density of a void having a circle equivalent diameter of 0.02 ?m to 3.0 ?m is 2000 mm?2 or less in the metallographic structure.

Abstract: Provided are a ferritic stainless steel and a method for producing the ferritic stainless steel. A ferritic stainless steel of the present invention contains, in terms of % by mass, C: 0.005% to 0.05%, Si: 0.02% to 0.50%, Mn: 0.05% to 1.0%, P: 0.04% or less, S: 0.01% or less, Cr: 15.5% to 18.0%, Al: 0.001% to 0.10%, N: 0.01% to 0.06%, V: 0.01% to 0.25%, Ti: 0.001% to 0.020%, Nb: 0.001% to 0.030%, and the balance being Fe and unavoidable impurities, in which V/(Ti+Nb)?2.0 is satisfied.

Abstract: The present invention relates to thin hot-rolled ultrahigh strength steel (UHSS) products, i.e. to hot-rolled steel strips with ultrahigh strength and good bendability. The object of the present invention is to provide an ultrahigh strength hot-rolled steel product that is having yield strength Rp0.2 at least 840 MPa and improved bendability. Further, a preferred aim is also to achieve an ultrahigh strength steel strip with excellent low temperature impact toughness. The inventors of the present invention have surprisingly found that the bendability of directly quenched ultrahigh strength steel strip can be significantly improved by producing a microstructure comprising upper bainite as main phase and by having a hot-rolled steel strip product having a yield strength Rp0.2 at least 840 MPa and a thickness of less than 12 mm, whose composition in percentage by weight is C: 0.03-0.08, Si: 0.01-0.8, Mn: 0.8-2.5, Al: 0.01-0.15, Cr: 0.01-2.0, B: 0.0005-0.005 Nb: 0.005-0.07, Ti: 0.005-0.12, N:<0.01, P:<0.

Abstract: Methods for recovering gold from gold-bearing materials are provided. The methods rely upon on the self-assembly of KAuBr4 and ?-cyclodextrin (?-CD) in aqueous solution to form a co-precipitate, a 1:2 complex, KAuBr4•(?-CD)2 (“?•Br”), either alone or in an extended {[K(OH2)6][AuBr4]?(?-CD)2}n chain superstructure (FIG. 1). The co-precipitation of ?•Br is selective for gold, even in the presence of other metals, including other square-planar noble metals. The method enables one to isolate gold from gold-bearing materials from diverse sources, as further described.

Abstract: The invention provides a continuous method for extracting transition metal, the method comprising: supplying a spent generator liquor comprising transition metal in highly alkaline solution; mixing the liquor with acid thereby generating a solution, wherein the transition metal resides within the solution; combining the solution with an organic liquid comprising tributyl phosphate or other neutral extractant to extract the transition metal within the organic liquid; washing the extracted transition metal in the organic liquid with acid so as to remove non-transition-metal salts from the organic liquid phase; and stripping the washed transition metal loadedorganic liquid phase with hydroxide, water or complexing agent to remove the transition metal from the organic phase.

Abstract: Provided is a hydrogen storage alloy which is characterized in that two or more crystal phases having different crystal structures are layered in a c-axis direction of the crystal structures. The hydrogen storage alloy is further characterized in that a difference between a maximum value and a minimum value of a lattice constant a in the crystal structures of the laminated two or more crystal phases is 0.03 ? or less.

Abstract: A Ni-based alloy having excellent hot forgeability and corrosion resistance includes, by mass %, Cr: more than 18% to less than 21%, Mo: more than 18% to less than 21%, Ta: 1.1% to 2.5%, Mg: 0.001% to 0.05%, N: 0.001% to 0.04%, Mn: 0.001% to 0.5%, Si: 0.001% to 0.05%, Fe: 0.01% to 1%, Co: 0.01% or more and less than 1%, Al: 0.01% to 0.5%, Ti: 0.01% or more and less than 0.1%, V: 0.005% or more and less than 0.1%, Nb: 0.001% or more and less than 0.1%, B: 0.0001% to 0.01%, Zr: 0.001% to 0.05%, and a balance consisting of Ni and unavoidable impurities.

Abstract: To obtain an Al—Mg—Si based aluminum alloy extruded material with a smooth surface and no burning without inhibiting the productivity. An aluminum alloy billet includes: Si: 2.0 to 6.0% by mass; Mg: 0.3 to 1.2% by mass; and Ti: 0.01 to 0.2% by mass, a Fe content being restricted to 0.2% or less by mass, with the balance being Al and inevitable impurities. The aluminum alloy billet is subjected to a homogenization treatment by keeping at 500 to 550° C. for 4 to 15 hours. The billet is forcibly cooled to 250° C. or lower at an average cooling rate of 50° C./hr or higher. Then, the billet is subjected to hot-extruding at an extrusion rate of 3 to 10 m/min by being heating at 450 to 500° C. The extruded material is forcibly cooled at an average cooling rate of 50° C./sec or higher and then subjected to an aging treatment. The extruded material can be manufactured that has its surface having a ten-point average roughness Rz of 80 ?m or less.

Abstract: The high alloy for oil well according to the present embodiment consists of, in mass %, C: 0.03% or less, Si: 1.0% or less, Mn: 0.05 to 1.5%, P: 0.03% or less, S: 0.03% or less, Ni: 26.0 to 40.0%, Cr: 22.0 to 30.0%, Mo: 0.01% or more to less than 5.0%, Cu: 0.1 to 3.0%, Al: 0.001 to 0.30%, N: more than 0.05% to 0.30% or less, O: 0.010% or less, and Ag: 0.005 to 1.0%, wherein the alloy satisfies the following Formulae (1) and (2), wherein the high alloy for oil well has yield strength of 758 MPa or more: 5×Cu+(1000×Ag)2?40 ??(1) Cu+6×Ag?500×(Ca+Mg+REM)?3.5 ??(2) where, each element symbol in each Formula is substituted by the content (in mass %) of each element.

Abstract: A lower carbon steel alloy with specific substitutional alloying additions. The alloy is useful in the production of ASTM A516 grade pressure vessel steel plates with excellent HIC resistance. The material has a ferrite-pearlite microstructure, in normalized and stress relieved condition, appropriate for resisting hydrogen induced cracking, with isolated ferrite and pearlite constituents and no continuous pearlite bands. The material exhibits significant low temperature toughness.

Abstract: Steel has a chemical composition that contains 0.050% to 0.40% of C, 0.50% to 3.0% of Si, 3.0% to 8.0% of Mn, and 0.001% to 3.0% of sol. Al, by mass %, and has a metallographic structure that contains 10% to 40% of austenite in terms of % by volume. The average concentration of C in austenite is 0.30% by 0.60%, by mass %, structure uniformity, which is represented by a value obtained by subtracting the minimum value from the maximum value of Vickers hardness that is measured, in the metallographic structure is 30 Hv or less, and the tensile strength is 900 MPa to 1800 MPa.